Materiały źródłowe

• #1 Pharmacological treatment for Buerger’s disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7104255/

  Buerger’s disease (thromboangiitis obliterans) is a nonatherosclerotic, segmental inflammatory pathology that most commonly affects the small and medium sized arteries, veins, and nerves in the upper and lower extremities. […] Pharmacological treatment is an option for patients with severe complications, such as ischaemic ulcers or rest pain. […] Five randomised controlled trials (total 602 participants) compared prostacyclin analogue with placebo, aspirin, or a prostaglandin analogue, and folic acid with placebo. […] Compared with aspirin, intravenous prostacyclin analogue iloprost improved ulcer healing (risk ratio (RR) 2.65; 95% confidence interval (CI) 1.15 to 6.11; 98 participants; one study; moderate quality evidence), and helped to eradicate rest pain after 28 days (RR 2.28; 95% CI 1.48 to 3.52; 133 participants; one study; moderate quality evidence).

• #1 Thromboangiitis Obliterans (Buerger Disease) Treatment & Management: Approach Considerations, Cessation of Tobacco Use, Pharmacologic Therapy

  https://emedicine.medscape.com/article/460027-treatment

  Except for absolute tobacco avoidance, no forms of therapy are definitive for thromboangiitis obliterans (TAO; also known as Buerger disease). […] There is some support for a few pharmacologic approaches, but for the most part, such approaches are ineffective. Surgical revascularization usually is not feasible, because of the lack of a distal target for revascularization. Endovascular options for treatment of occlusive lesions are growing in popularity. […] Patients may require one or more amputations. […] Absolute discontinuance of tobacco use is the only strategy proven to prevent the progression of TAO. Smoking as few as one or two cigarettes daily, using chewing tobacco, or even using nicotine replacements may keep the disease active. […] […] Intravenous (IV) iloprost (a prostaglandin analogue), an expensive agent unavailable in the United States, appears to be somewhat effective in improving symptoms, accelerating resolution of distal-extremity trophic changes, and reducing the amputation rate among patients with TAO. […] Aside from the experimental use of iloprost and thrombolytics, the use of antibiotics to treat infected ulcers, and the palliative treatment of ischemic pain with NSAIDs and narcotics, all other forms of pharmacologic treatment have been generally ineffective in the treatment of TAO, including steroids, calcium-channel blockers, reserpine, pentoxifylline, vasodilators, antiplatelet drugs, and anticoagulants.

• #1 Buerger’s Disease: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/21680-buergers-disease

  Theres no cure for Buergers disease, but stopping all tobacco, marijuana and nicotine use is the best way to keep Buergers disease from getting worse. […] When people with Buergers disease stop smoking, their symptoms usually get better. In some people, the disease goes into remission (becomes inactive) once they stop smoking. […] Specific medicines can help with your Buergers disease symptoms. […] Some medications are helpful in Buergers disease treatment, including: Vasodilators, like calcium channel blockers, to make your blood flow better. […] You may get relief from Buergers disease symptoms with: Exercise. […] The best thing you can do is to stop using any type of tobacco to keep Buergers disease from getting worse. […] About 50% of the people with Buergers disease who keep using tobacco end up needing to have a finger or toe removed (amputation). People with Buergers disease who quit smoking hardly ever need an amputation. […] Buergers disease is a rare issue with the blood vessels in your fingers, toes, arms and legs. While you can take medicines for your symptoms, the best treatment for Buergers disease is to quit smoking. Most people with Buergers disease get relief from their symptoms when they stop smoking.

• #1 Pharmacological treatment for Buerger’s disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7104255/

  Moderate quality evidence suggests that intravenous iloprost (prostacyclin analogue) is more effective than aspirin for eradicating rest pain and healing ischaemic ulcers in Buerger’s disease, but oral iloprost is not more effective than placebo. […] Very low and low quality evidence suggests there is no difference between prostacyclin (iloprost and clinprost) and the prostaglandin analogue alprostadil for healing ulcers and relieving pain respectively in severe Buerger’s disease. […] Very low quality evidence suggests there is no difference in pain scores and amputation rates between folic acid and placebo, in people with Buerger’s disease and hyperhomocysteinaemia. […] Further high quality trials assessing the effectiveness of pharmacological agents (intravenous or oral) in patients with Buerger’s disease are needed.

• #1 Thromboangiitis Obliterans (Buerger Disease) Medication: Nonsteroidal Anti-Inflammatory Drugs, Analgesics

  https://emedicine.medscape.com/article/460027-medication

  The goals of pharmacotherapy are to treat pain and reduce morbidity. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) and narcotic analgesics can be administered to palliate ischemic pain. […] NSAIDs have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclooxygenase (COX) activity and prostaglandin synthesis. […] Naproxen is used for the relief of mild to moderate pain. It inhibits inflammatory reactions and pain by decreasing COX activity, which results in decreased prostaglandin synthesis. […] Ibuprofen is the drug of choice (DOC) for patients with mild to moderate pain. It inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. […] Indomethacin is used for relief of mild to moderate pain; it inhibits inflammatory reactions and pain by decreasing the activity of COX, which results in a decrease of prostaglandin synthesis.

• #1 Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)

  https://www.mdpi.com/2227-9717/8/11/1408

  If TAO patients are left untreated, the disease is likely to progress to amputation. […] All patients with TAO are advised to stop smoking and avoid second-hand smoke exposure. […] Pharmacological treatment of TAO is focused on anticoagulation (Aspirin), vasodilators (calcium channel blockers), systemic anti-inflammatory drugs (prostacyclins analogs) and analgesics. […] Surgical modalities such as revascularization offer limited efficacy for the treatment of TAO patients with clinical symptoms such as rest pain, claudication, ulceration, and gangrene. […] In 1998, a benchmark publication demonstrated that vascular endothelial growth factor (VEGF) gene transfer shows utility in the treatment of TAO. […] Clinical trials have evaluated the potential benefits of stem cell therapy in CLI, which has similar clinical symptoms as TAO.

• #1 Thromboangiitis Obliterans (Buerger Disease) Treatment & Management: Approach Considerations, Cessation of Tobacco Use, Pharmacologic Therapy

  https://emedicine.medscape.com/article/460027-treatment

  Hyperbaric oxygen therapy is now an accepted adjunctive measure that has been shown to provide significant clinical improvement in patients with diabetic wounds, refractory osteomyelitis, acute limb ischemia, or necrotizing soft-tissue infection. […] Its use in treating TOA patients without revascularization options remains experimental; the available data are extremely limited. […] Because of the diffuse segmental nature of TAO and the diseases predilection for small and medium-sized arteries, surgical revascularization for TAO usually is not feasible. […] The ultimate surgical therapy for refractory TAO (in patients who continue smoking) is distal limb amputation for nonhealing ulcers, gangrene, or intractable pain. Amputation should be avoided whenever possible, but if it is necessary, it should be performed in a way that preserves as much of the limb as possible. […] Endovascular options for treatment of occlusive lesions in TAO are becoming increasingly popular, with moderate- and long-term success seen in selected patients. […] Clinical outcomes appear to be improved when interventions are combined with smoking cessation.

• #1 Buerger disease | Altru Health System

  https://www.altru.org/health-library/conditions/buerger-disease

  During compression therapy, you wear a sleeve over the affected arm or leg. The sleeve connects to a pump. The pump sends air into the sleeve on and off. The sleeve inflates, gently squeezing the affected body area. The pressure increases blood flow to the area. […] Surgery may be needed to remove an arm or leg that’s infected or has dead tissue. This surgery is called amputation.

• #1

  https://vimvigr.com/blogs/our-blog/buergers-disease-treatment?srsltid=AfmBOopt5Z1isNILyvWjev75Jg9LU_N51u3QZT_XYq69JC6o1HN0U08L

  Buergers disease – also known medically as thromboangiitis obliterans – causes blood vessels to swell, particularly in the arms and legs. […] To relieve these symptoms, compression socks can be worn to boost peripheral circulation, reduce swelling, and provide additional support for walking. […] Although there is no cure for Buergers disease, doctors and medical professionals might offer compression therapy to Buergers disease patients to stimulate better blood flow in the feet and hands. […] The primary benefit of compression socks is that they improve blood flow in the lower limbs. […] Wearing compression socks while walking has been shown by scientific studies to be effective in reducing these cases of swelling and improving overall comfort for patients. […] Doctors regularly prescribe compression socks to those recovering from surgery (especially those who are bed-ridden) for this reason.

• #1 Buerger’s Disease: Clinical Aspects and Evidence-Based Treatments | IntechOpen

  https://www.intechopen.com/chapters/59613

  The surgical revascularization of limbs in patients with BD is controversial due to the high index of graft occlusion. […] Surgical treatment through lumbar sympathectomy is a surgical modality used to prevent amputations and for alleviation of pain at rest through the vasodilatory effects, resulting from a decreased sympathetic response in the affected limb. […] Pharmacological treatment in patients with Buergers disease is an alternative for selected cases when the disease presents as diffuse and severe limb ischemia. […] It is important to cite the degree of evidence of these treatments. […] The comparison of lumbar sympathectomy, one of the most used treatments in patients with thromboangiitis obliterans with ischemic ulcers and pain at rest with other therapies, was carried out by a recently published systematic review with a finding of very low evidence suggests that intravenous iloprost (prostacyclin analogue) is more effective than the lumbar sympathectomy in the healing of ischemic ulcers and pain at rest in patients with Buerger’s disease.

• #1 Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)

  https://www.mdpi.com/2227-9717/8/11/1408

  Buerger’s disease or Thromboangiitis Obliterans (TAO) is a nonatherosclerotic segmental vascular disease which affects small and medium arteries and veins in the upper and lower extremities. […] There is no definitive cure for this disease as therapeutic modalities are limited in number and efficacy. […] Recently, studies have shown that therapeutic angiogenesis and immunomodulatory approaches through the delivery of stem cells to target tissues are potential options for ischemic lesion treatment. […] Despite considerable advances in treatment options, TAO is still associated with high morbidity. […] While pharmacological approaches and surgical intervention remain generally palliative, novel therapeutic approaches such as gene and stem cell therapy to promote angiogenesis have been considered promising for the treatment of TAO.

• #1 UM Spinoff Achieves FDA Orphan Drug Status for Buerger’s Disease – InventUMPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–button

  https://news.med.miami.edu/um-spinoff-achieves-fda-orphan-drug-status-for-buergers-disease/

  A biotech company that emanated from the Miller School’s Omaida Velazquez, M.D., professor and chair of the Dewitt Daughtry Family Department of Surgery, and Zhao-Jun Liu, M.D., Ph.D., associate professor of the Dewitt Daughtry Family Department of Surgery, has achieved a major milestone. The company, Ambulero, Inc., is developing new cell and gene therapy treatments for patients suffering from severe vascular disease. The FDA’s Office for Orphan Products Development has granted the company’s request for orphan drug status for its gene therapy candidate, AMB-301, to treat Buerger’s disease. […] There are no effective treatments, making any new therapies critically important. […] AMB-301 is a promising gene therapy candidate for enhancing blood vessel formation, restoring tissue integrity, and eliminating the need for amputation as a treatment.

• #1

  https://www.healio.com/news/hematology-oncology/20210308/fda-grants-orphan-drug-designation-to-cell-therapy-for-buergers-disease

  The FDA granted orphan drug designation to CLBS12, an investigational nongene-edited cell therapy for the treatment of Buergers disease, according to the agents manufacturer. […] Without a currently approved or effective treatment for this condition in the U.S., a significant unmet need remains for therapies that slow, stop or, ideally, reverse this debilitating disease. […] CLBS12 is being evaluated for critical limb ischemia and Buergers disease in an open-label, phase 2 study based in Japan. […] Achieving orphan designation for CLBS12 takes us one step closer to realizing our goal of fulfilling the unmet medical need for [patients with Buergers disease] around the world.

• #1 Herbal therapy treatment in thromboangiitis obliterans: a retrospective clinical study – Li – Annals of Palliative Medicine

  https://apm.amegroups.org/article/view/47023/html

  The focus of the study is to elicit the efficacy of the addition of Herbal therapy treatment to conventional treatment in TAO patients with severe extremity pain and to assess any statistically significant benefits in patients pain control at rest. […] The addition of herbal therapy treatment can augment conventional treatments in TAO patients by improving or eliminating intermittent claudication symptoms, prolonging claudication distance, and reducing total blood viscosity. […] The purpose of this study was to investigate the effect of topical Herbal therapy treatment on patient outcomes in patients with TAO. […] The addition of Herbal therapy treatment to conventional treatment in TAO patients with severe extremity pain was associated with a reduction of rest pain and intermittent claudication.

• #1 Buerger’s Disease | Neuromodulation Center

  https://www.neuromodulationinturkey.com/disease/buergers-disease/12

  Spinal Cord Stimulation (SCS) has emerged as a groundbreaking treatment for Buerger’s Disease, offering a novel approach to managing its symptoms and potentially saving patients’ extremities. […] In the context of Buerger’s Disease, SCS can offer multiple benefits. It has been shown to reduce the severe pain associated with the condition, potentially allowing patients to avoid or decrease their use of narcotic medications. More remarkably, SCS can also improve the vascularity of the affected limbs and, over time, increase blood flow, which may ultimately heal the areas of tissue damage and prevent amputation. […] Several clinical studies have reported significant success in the use of SCS for Buerger’s Disease. The devices have shown to not only alleviate pain but also to enhance the healing of ulcers and reduce the likelihood of amputation.

• #1 Buerger’s Disease: Symptoms and Treatment | Doctor

  https://patient.info/doctor/buergers-disease-pro

  Patients with Buerger’s disease must be advised to stop smoking immediately and completely. This is the only treatment known to be effective. Otherwise, there is not yet an agreed consensus on the treatment of choice. […] Supportive measures include: Gentle massage and warmth to increase circulation. Avoiding conditions that reduce peripheral circulation, like cold temperatures. Avoiding sitting or standing in one position for long periods. Not walking barefoot, to avoid injury. Avoiding tight or restrictive clothing. Aggressive treatment of any injuries (such as ulcers). […] Although low-dose aspirin has been used, the drug iloprost (a prostacyclin analogue) has been shown in the latest Cochrane review to be superior to aspirin when given intravenously. However, oral iloprost is not superior to placebo.

• #1 Buergers Disease – Vasculitis UK

  https://www.vasculitis.org.uk/about-vasculitis/buergers-disease

  Overall, the quality of the evidence was very low to moderate, with few studies, small numbers of participants, variation in severity of disease of participants between studies and missing information regarding for example baseline tobacco exposure. High quality trials assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buergers disease are needed.

• #1 Thromboangiitis Obliterans (Buerger’s Disease)

  https://www.acc.org/Latest-in-Cardiology/Articles/2019/10/21/15/05/Thromboangiitis-Obliterans

  Buerger’s disease or Thromboangiitis Obliterans (TAO) is a segmental non-atherosclerotic inflammatory condition that affects the small and medium sized arteries and veins of the extremities. […] Complete cessation of all tobacco products is the mainstay of treatment. […] In additional to smoking cessation, patients should be educated on proper skin hygiene, daily foot checks, and proper footwear (to avoid trauma/rubbing). […] Vasodilator therapy with calcium channel blockers, nitrates, prostacyclin and phosphodiesterase inhibitors may theoretically alleviate symptoms of vasospasm. […] Endovascular therapies are usually not indicated in TAO due to the distal nature of the disease. […] Based on limited data, hyperbaric oxygen therapy (HBOT) may provide some benefit in TAO. […] Bosentan therapy was described in a case series of eight patients who failed aggressive medical therapy with antiplatelet therapy, vasodilators and IV Alprostadil. […] Long term clinical benefits were observed in a small group of patients with that received BM-MNC. […] Despite being described over a century ago, TAO remains poorly understood and challenging to treat.

• #1 Buerger’s Disease | The Foundation to Advance Vascular Cures

  https://www.vascularcures.org/buergers-disease

  In patients who smoke, the treatment for TAO is immediate and complete tobacco cessation. It is absolutely essential. Mayo Clinic physicians have found that TAO patients who continue to smoke had a high rate of amputation that persists up to 17 years after first diagnosis. […] The risk of amputation in TAO patients who stop smoking is much lower.

• #2 Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)

  https://www.mdpi.com/2227-9717/8/11/1408

  Buerger’s disease or Thromboangiitis Obliterans (TAO) is a nonatherosclerotic segmental vascular disease which affects small and medium arteries and veins in the upper and lower extremities. […] There is no definitive cure for this disease as therapeutic modalities are limited in number and efficacy. […] Recently, studies have shown that therapeutic angiogenesis and immunomodulatory approaches through the delivery of stem cells to target tissues are potential options for ischemic lesion treatment. […] Despite considerable advances in treatment options, TAO is still associated with high morbidity. […] While pharmacological approaches and surgical intervention remain generally palliative, novel therapeutic approaches such as gene and stem cell therapy to promote angiogenesis have been considered promising for the treatment of TAO.

• #2 Buerger Disease | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/18685

  The treatment of TAO revolves around strict smoking cessation. In patients who can abstain, disease remission is impressive, and amputation avoidance is increased. […] Although there is no cure for Buerger disease, the cornerstone of management is smoking cessation. Even smoking 1 or 2 cigarettes per day can perpetuate the disease. Even the use of nicotine replacement therapy can keep the disease active. […] Symptomatic management with calcium channel blockers or other vasodilators can be implemented, especially if there is a concurrent Raynaud phenomenon. Prostaglandin analogs such as intravenous iloprost can be used to treat pain and ischemic complications. […] Intravenous (IV) iloprost appears to be helpful in relieving symptoms, improving distal-extremity trophic changes, and decreasing the amputation rate in patients suffering from Buerger disease.

• #2 Update on Thromboangiitis Obliterans (Buerger’s Disease) | AAFP

  https://www.aafp.org/pubs/afp/issues/2001/0315/p1195.html

  The only truly effective treatment for thromboangiitis obliterans is smoking cessation or discontinuation of tobacco-containing products. In one study, 94 percent of affected persons who quit smoking avoided amputations compared with 57 percent who continued to smoke. […] Therapy with intravenous iloprost (a prostaglandin analog) has been studied. This agent was found to be superior to aspirin in producing clinical improvement and decreasing the need for amputation. It is not currently available in the United States. […] Experience with intra-arterial thrombolytic therapy is limited to a few trials that have shown moderate success, but more studies are needed. Surgical revascularization is not feasible because of the diffuse segmental involvement and the distal nature of the vascular involvement.

• #2 Buerger’s Disease | The Foundation to Advance Vascular Cures

  https://www.vascularcures.org/buergers-disease

  In patients who smoke, the treatment for TAO is immediate and complete tobacco cessation. It is absolutely essential. Mayo Clinic physicians have found that TAO patients who continue to smoke had a high rate of amputation that persists up to 17 years after first diagnosis. […] The risk of amputation in TAO patients who stop smoking is much lower.

• #2 Buergers Disease – Vasculitis UK

  https://www.vasculitis.org.uk/about-vasculitis/buergers-disease

  It is essential that people affected with Buergers Disease stop smoking completely and immediately. Continued smoking or use of other forms of tobacco, even small amounts, increases the risk of losing fingers, toes or limbs due to necessary amputation. […] Anti-inflammatory and immunosuppressant treatments have not been shown to be effective in Buergers Disease. Other treatments such as iloprost or prostacyclin that help to open up the blood vessels may be helpful. […] Moderate quality evidence from one study suggested that intravenous iloprost was effective in healing ulcers and relieving rest pain after 28 days of treatment when compared with oral aspirin, but no differences were found in the rates of amputation. […] Evidence from two studies suggested that prostacyclin was as effective as prostaglandin analogues in healing ulcers (very low quality evidence) and eradicating pain at rest (low quality evidence), but rates of amputation were not assessed.

• #2 Pharmacological treatment (drugs) for Buerger’s disease | Cochrane

  https://www.cochrane.org/CD011033/pharmacological-treatment-drugs-buergers-disease

  Moderate-certainty evidence from one study suggested that there was no clear difference between placebo and the oral prostacyclin analogue iloprost (200 mcg and 400 mcg) in healing ischaemic ulcers or eradicating pain at rest after eight weeks and six months, and rates of amputation after six months. […] Treatment side effects, such as headaches or nausea, did not result in treatment interruptions or more serious consequences. […] Moderate-certainty evidence suggests that intravenous iloprost (prostacyclin analogue) is more effective than aspirin for eradicating rest pain and healing ischaemic ulcers in Buergers disease, but oral iloprost is not more effective than placebo. […] Further well designed RCTs assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger’s disease are needed.

• #2 Buerger Disease | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/18685

  Nonsteroidal anti-inflammatory drugs (NSAIDs) and narcotic analgesia can be prescribed to palliate pain secondary to ischemia, and appropriate antibiotics can be given to manage mild distal extremity ulcers. […] Hyperbaric oxygen therapy is a widely accepted adjunctive treatment option that provides significant improvement in patients having diabetic wounds, refractory osteomyelitis, limb ischemia, or necrotizing infection of the soft tissues. […] Because of the diffuse segmental involvement of Buerger disease and its propensity to affect small and medium-sized arteries, surgical revascularization is usually not advisable. The ultimate surgical treatment for the refractory disease in patients who do not quit smoking is distal limb amputation for non-resolving ulcers, gangrene, or persistent pain. Whenever possible, amputation should be avoided. […] Surgical revascularization is usually not indicated due to the distal nature of the occlusive disease and because most patients do well with smoking cessation. It is accepted that surgery is rarely needed if the patient can stop smoking.

• #2 Buerger’s disease medical therapy – wikidoc

  https://www.wikidoc.org/index.php/Buerger%27s_disease_medical_therapy

  Iloprost is especially effective in the intravenous form at reducing pain symptoms, better than low dose aspirin or lumbar sympathectomy. […] Calcium channel blockers are used in patients whose main complaint is Raynaud phenomenon. […] Intermittent pneumatic compression (IPC) is used in patients whose main complaint is that of poor circulation and healing in the extremities. […] Immunoabsorption therapy and bosentan (endothelin receptor antagonist) have demonstrated that they are effective in improving pain intensity and ulcer healing. […] Non-steroidal anti-inflammatory drugs may be used to relieve pain symptoms, including naproxen, ibuprofen, indomethacin, diclofenac, and ketofen.

• #2 Buerger disease | UM Health-Sparrow

  https://www.uofmhealthsparrow.org/departments-conditions/conditions/buerger-disease

  A medicine called bosentan (Tracleer) may be tried if you have very severe Buerger disease symptoms. It’s approved to treat high blood pressure in the lungs. But a few studies showed that it improved blood flow in people with Buerger disease. […] If you have Buerger disease, your provider may suggest a medicine-free treatment called compression therapy. Your health care provider may call this treatment intermittent pneumatic compression pumping. This treatment puts pressure on the affected body area to improve blood flow. […] Surgery may be needed to remove an arm or leg that’s infected or has dead tissue. This surgery is called amputation.

• #2

  https://vimvigr.com/blogs/our-blog/buergers-disease-treatment?srsltid=AfmBOopt5Z1isNILyvWjev75Jg9LU_N51u3QZT_XYq69JC6o1HN0U08L

  Through the increase in blood flow, compression socks may support quicker healing in the lower legs. […] In addition to the improvements in blood flow, which can lower the risk of the lower legs going numb or tingling, compression socks also provide a beneficial massage to the area. […] Wearing compression socks is a convenient and simple solution to help reduce the symptoms of Buergers disease that you can implement in your everyday life. […] Quitting smoking is the key Buergers disease treatment that patients should perform, according to the Mayo Clinic. […] Medications to improve blood flow can be appropriate for Buergers disease patients. […] The severe lack of blood flow that Buergers disease can cause may lead to very damaged skin tissues. […] Along with quitting smoking, you can improve your health when suffering from Buergers disease with a few additional steps.

• #2 Vascular Treatment for Buerger’s Disease – Evansville Surgical Associates

  https://www.evansvillesurgical.com/vascular-treatment-for-buergers-disease/

  Vascular treatment for Buergers disease is reserved for severe cases. In situations like these, the Vascular Surgical Associates team in Evansville, IN, may consider the following interventions: Endovascular procedures, Bypass surgery, Sympathectomy. […] Endovascular procedures like angioplasty or stenting might be attempted to improve blood flow in larger affected vessels. […] Bypass surgery aims to reroute blood flow around blocked arteries to improve circulation in the affected limb. […] Sympathectomy involves surgically cutting the sympathetic nerves to reduce arterial spasms and potentially improve blood flow. […] Its important to remember that these surgical interventions are typically considered only in severe cases. At Vascular Surgical Associates in Evansville, IN, this includes when conservative treatments have failed and you have successfully quit smoking. […] Treatment focuses on smoking cessation, symptom management medications, and surgical options in severe cases, with better outcomes for those who quit tobacco.

• #2 Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)

  https://www.mdpi.com/2227-9717/8/11/1408

  If TAO patients are left untreated, the disease is likely to progress to amputation. […] All patients with TAO are advised to stop smoking and avoid second-hand smoke exposure. […] Pharmacological treatment of TAO is focused on anticoagulation (Aspirin), vasodilators (calcium channel blockers), systemic anti-inflammatory drugs (prostacyclins analogs) and analgesics. […] Surgical modalities such as revascularization offer limited efficacy for the treatment of TAO patients with clinical symptoms such as rest pain, claudication, ulceration, and gangrene. […] In 1998, a benchmark publication demonstrated that vascular endothelial growth factor (VEGF) gene transfer shows utility in the treatment of TAO. […] Clinical trials have evaluated the potential benefits of stem cell therapy in CLI, which has similar clinical symptoms as TAO.

• #2 UM Spinoff Achieves FDA Orphan Drug Status for Buerger’s Disease – InventUMPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–buttonPage 1arrow–button

  https://news.med.miami.edu/um-spinoff-achieves-fda-orphan-drug-status-for-buergers-disease/

  “Current day standard of care for BD patients addresses only the initiating modifiable risk factors. However, for the restoration of the vascular tissue damage at diagnosis, or the halting of disease progression, no therapies have been developed to-date,” said Dr. Velazquez, who is a renowned expert in treating vascular disease. “AMB-301 is a promising new drug candidate. It brings hope to BD patients who often suffer debilitating major limb amputations.” […] “Receiving orphan drug designation for AMB-301 is an important milestone to emerge from our vascular research program. We are pleased with this achievement and believe AMB-301 would address a significant unmet medical need for BD patients, if approved.” […] “We believe our first-in-class gene therapy platform will provide new treatment options to patients suffering from BD and potentially other severe vascular diseases.”

• #2 Herbal therapy treatment in thromboangiitis obliterans: a retrospective clinical study – Li – Annals of Palliative Medicine

  https://apm.amegroups.org/article/view/47023/html

  In conclusion, the addition of Herbal therapy treatment to conventional treatment in TAO patients with severe extremity pain conferred statistically significant benefits in terms of rest pain control. It also could improve or eliminate intermittent claudication, prolong claudication distance, increase ABI, and reduce total blood viscosity. At the same time, Tuoju lotion can improve microcirculation status in the short term.

• #2 Buerger’s Disease | Neuromodulation Center

  https://www.neuromodulationinturkey.com/disease/buergers-disease/12

  The potential for SCS in transforming the management of Buerger’s Disease is immense. Not only does it address the immediate concern of pain control, but it also provides a pathway towards functional recovery and the preservation of limbs. […] The integration of SCS into a multidisciplinary approach that includes smoking cessation, pharmacological therapy, and vascular surgery can offer a comprehensive treatment package. […] By targeting the root cause of the pain and augmenting blood flow to the affected areas, SCS stands as a groundbreaking intervention with the potential to salvage limbs and restore dignity and functionality to those afflicted by the disease.

• #2 Buerger’s Disease Doctor Mumbai, Buerger’s Disease Treatment

  https://www.drpankajpatel.com/buergers-disease.html

  The cornerstone of treatment is to stop smoking completely. In addition the treatment also focuses on removing all factors that may reduce blood supply […] Abstain from tobacco use in all forms […] Avoid drugs which constrict the blood vessels […] Avoid injury from heat or cold […] Avoid tight or restrictive clothing […] Avoid sitting or standing in one position for long periods […] Avoid walking barefoot in order to avoid injury […] Wear properly fitting shoes and stockings […] Avoid minor surgery of the toes unless performed by experienced surgeons […] Seek treatment for fungal infections immediately […] Report all injuries to your family care physician for appropriate treatment […] Surgical Bypass and angioplasty can be done if the distal vessels are good […] Chemical sympathectomy still has a role in relieving pain […] Prostaglandin injections have encouraging results.

• #2 Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)

  https://www.mdpi.com/2227-9717/8/11/1408

  It has been recently reported that cell therapy using mononuclear stem cells (MNCs), endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs), and pluripotent stem cells (PSCs) may have useful roles in prevention of the progression of disease and reduction in major amputation rates. […] Studies have revealed that paracrine factors secreted by UC-MSC stimulate angiogenesis. […] A seven-patient phase I trial using adipose-derived stroma cells strongly improved revascularization and tissue perfusion in CLI. […] In the past two decades, stem cell-based therapy has demonstrated clinical efficacy in the form of therapeutic angiogenesis in peripheral vascular disease.

• #3 Pharmacological treatment for Buerger’s disease – Cacione, DG – 2016 | Cochrane Library

  https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011033.pub3/full

  Buerger’s disease (thromboangiitis obliterans) is a nonatherosclerotic, segmental inflammatory pathology that most commonly affects the small and medium sized arteries, veins, and nerves in the upper and lower extremities. […] Pharmacological treatment is an option for patients with severe complications, such as ischaemic ulcers or rest pain. […] To assess the effectiveness of any pharmacological agent (intravenous or oral) compared with placebo or any other pharmacological agent in patients with Buerger’s disease. […] Five randomised controlled trials (total 602 participants) compared prostacyclin analogue with placebo, aspirin, or a prostaglandin analogue, and folic acid with placebo. […] Compared with aspirin, intravenous prostacyclin analogue iloprost improved ulcer healing (risk ratio (RR) 2.65; 95% confidence interval (CI) 1.15 to 6.11; 98 participants; one study; moderate quality evidence), and helped to eradicate rest pain after 28 days (RR 2.28; 95% CI 1.48 to 3.52; 133 participants; one study; moderate quality evidence), although amputation rates were similar six months after treatment (RR 0.32; 95% CI 0.09 to 1.15; 95 participants; one study; moderate quality evidence).

• #3 Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)

  https://www.mdpi.com/2227-9717/8/11/1408

  It has been recently reported that cell therapy using mononuclear stem cells (MNCs), endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs), and pluripotent stem cells (PSCs) may have useful roles in prevention of the progression of disease and reduction in major amputation rates. […] Studies have revealed that paracrine factors secreted by UC-MSC stimulate angiogenesis. […] A seven-patient phase I trial using adipose-derived stroma cells strongly improved revascularization and tissue perfusion in CLI. […] In the past two decades, stem cell-based therapy has demonstrated clinical efficacy in the form of therapeutic angiogenesis in peripheral vascular disease.

Zobacz więcej